Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 12;23(3):27.
doi: 10.1007/s11912-021-01021-1.

Acute Leukemia in Infants

Azada Ibrahimova  1 , Lauren Pommert  1   2 , Erin H Breese  3   4
Affiliations
Review

Acute Leukemia in Infants

Azada Ibrahimova et al. Curr Oncol Rep. .

Abstract

Purpose of the review: Infant leukemia is a rare, distinct subgroup of pediatric acute leukemias diagnosed in children under 1 year of age and characterized by unique, aggressive biology. Here, we review its clinical presentation, underlying molecular biology, current treatment strategies, and novel therapeutic approaches.

Recent findings: Infant leukemias are associated with high-risk molecular features and high rates of chemotherapy resistance. International collaborative clinical trials have led to better understanding of the underlying molecular biology, refined risk-based stratification, and investigated the use of hematopoietic stem cell transplantation. However, intensification of chemotherapy has failed to improve outcomes, and current regimens are associated with significant treatment-related and long-term toxicities. Infants with leukemia remain a challenging group to treat. We must continue collaborative efforts to move beyond traditional cytotoxic chemotherapy, incorporate molecularly targeted strategies and immunotherapy, and increase access to clinical trials to improve outcomes for this high-risk group of patients.

Keywords: “Acute lymphoblastic leukemia”; “Acute myeloid leukemia”; “Infant leukemia”; “KMT2A rearrangement”.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Surveillance Research Program, National Cancer Institute., https://seer.cancer.gov/explorer/ . Accessed 2020 Aug 8.
    1. Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. Blood. 2000;96(1):24–33. - DOI
    1. Chessells JM, Harrison CJ, Kempski H, Webb DK, Wheatley K, Hann IM, et al. Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC childhood Leukaemia working party. Leukemia. 2002;16(5):776–84. https://doi.org/10.1038/sj.leu.2402468 . - DOI - PubMed
    1. Hilden JM, Dinndorf PA, Meerbaum SO, Sather H, Villaluna D, Heerema NA, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's oncology group. Blood. 2006;108(2):441–51. https://doi.org/10.1182/blood-2005-07-3011 . - DOI - PubMed - PMC
    1. Reaman GH, Sposto R, Sensel MG, Lange BJ, Feusner JH, Heerema NA, et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999;17(2):445–55. https://doi.org/10.1200/jco.1999.17.2.445 . - DOI

Substances

LinkOut - more resources